Abstract Search

ey0018.8-3 | Important for Clinical Practice | ESPEYB18

8.3. Modified-release hydrocortisone in congenital adrenal hyperplasia

DP Merke , A Mallappa , W Arlt , A Brac de la Perriere , A Linden Hirschberg , A Juul , J Newell-Price , CG Perry , A Prete , DA Rees , N Reisch , N Stikkelbroeck , P Touraine , K Maltby , FP Treasure , J Porter , RJ Ross

J Clin Endocrinol Metab 2021; 106(5): e2063e2077.https://pubmed.ncbi.nlm.nih.gov/33527139/The authors report the findings of a 6-month, randomized, phase 3 trial, with a single arm extension, to investigate the efficacy, safety and tolerability of modified release hydrocortisone (MC-HC) replacement therapy versus standard glucocorticoid replacement therapy in 122 adult patients with c...

0 shares

ey0017.8-5 | Important for Clinical Practice | ESPEYB17

8.5. Exposure to glucocorticoids in the first part of fetal life is associated with insulin secretory defect in adult humans

JP Riveline , B Baz , JL Nguewa , T Vidal-Trecan , F Ibrahim , P Boudou , E Vicaut , A Brac de la Perriere , S Fetita , B Breant , B Blondeau , V Tardy-Guidollet , Y Morel , JF Gautier

To read the full abstract: J Clin Endocrinol Metab. 2020; 105(3): dgz145. PMID: 31665349.Prenatal treatment with glucocorticoids (GC) is used in several clinical indications. However, the long-term outcome on offspring metabolic, somatic and cognitive health has raised significant concern. In rodents, high glucocorticoid levels inhibit development of beta cells during fetal life and lead to...

0 shares

ESPE Yearbook of Paediatric Endocrinology

8.3. Modified-release hydrocortisone in congenital adrenal hyperplasia

8.5. Exposure to glucocorticoids in the first part of fetal life is associated with insulin secretory defect in adult humans

BiosciAbstracts